ProBioGen expands protein and virus manufacturing to drive continued growth

09-Jan-2025
ProBioGen

ProBioGen announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for proteins as well as the completion of the construction phase of its virus manufacturing unit.

In the protein vertical, this strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development through to commercial manufacturing. Utilizing its CHO.RiGHT® platform in combination with market-approved technologies such as the DirectedLuck® transposase and the ADCC enhancement GlymaxX®, ProBioGen reinforces its position as a reliable partner in the industry. With this investment the company strengthens its footprint in the market and is advancing its state-of-the-art facilities across two manufacturing sites.

In the viral vector arena, ProBioGen is building on a broad experience in developing proprietary viral manufacturing platforms to offer solutions that go beyond standard processes. The company provides tailored cell lines for producing viral vectors and virus-like particles (VLPs). This includes customized stable cell line development for lentiviral (LV) and adeno-associated virus (AAV) production, addressing the unique challenges of emerging therapeutic platforms and enabling the creation of next-generation therapies with precision and efficiency.

"These strategic initiatives mark a major milestone for us as we continue to grow and better fulfill our customer's needs.", explained Dr. Alfred Merz, Chief Executive Officer at ProBioGen.

Other news from the department manufacturing

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Sensirion opens additional production building in Debrecen

Sensirion opens additional production building in Debrecen

Frank Winkler receives the Brain Prize 2025 - The interaction between the nervous system and cancer is increasingly coming into focus

Frank Winkler receives the Brain Prize 2025 - The interaction between the nervous system and cancer is increasingly coming into focus

CorTec Welcomes Dr. Frank Desiere as Chief Executive Officer - A Strengthened Leadership Team to Accelerate Growth and Innovation

CorTec Welcomes Dr. Frank Desiere as Chief Executive Officer - A Strengthened Leadership Team to Accelerate Growth and Innovation

New Leadership at Andreas Hettich GmbH - After 20 years of successful leadership by the Eberle family, the Hettich Group is entering a new, forward-looking phase

New Leadership at Andreas Hettich GmbH - After 20 years of successful leadership by the Eberle family, the Hettich Group is entering a new, forward-looking phase

Managing Director Peter Sölkner leaves Vetter - Managing Director Carsten Press takes over the relevant departments

Managing Director Peter Sölkner leaves Vetter - Managing Director Carsten Press takes over the relevant departments

Turning fallen leaves into sustainably made paper - Ukrainian scientist selected as a finalist for the Young Inventors Prize 2024

Turning fallen leaves into sustainably made paper - Ukrainian scientist selected as a finalist for the Young Inventors Prize 2024

Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand - Albert M. Baehny will retire from Lonza Group following a transition period

Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand - Albert M. Baehny will retire from Lonza Group following a transition period

Dr. Roland Durner becomes new CEO of Bioengineering AG

Dr. Roland Durner becomes new CEO of Bioengineering AG

GDCh Award for Biocatalysis for Sebastian Gergel

GDCh Award for Biocatalysis for Sebastian Gergel

Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG - Grosse to take over as Group CEO on July 1, 2025

Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG - Grosse to take over as Group CEO on July 1, 2025

WACKER BIOSOLUTIONS under New Leadership - Susanne Leonhartsberger will leave the company at her own request at the end of 2024.

WACKER BIOSOLUTIONS under New Leadership - Susanne Leonhartsberger will leave the company at her own request at the end of 2024.